The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.
Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
Open accessAbstract
Type 2 diabetes is characterized by a deficit in β-cell mass, impaired insulin secretion in response to various stimuli (1–3), as well as a variable extent of insulin resistance (4). More specifically, regarding β-cell function, a significant reduction of the incretin effect, i.e., the postprandial augmentation of insulin secretion by gut hormones, has been described in patients with type 2 diabetes (5). Thus, while the two incretin hormones gastric inhibitory polypeptide (glucose-dependent insulinotopic polypeptide [GIP]) and glucagon-like peptide 1 (GLP-1) are held responsible for ∼50–70% of the postprandial insulin responses in healthy individuals (6), their contribution to the overall insulin responses after oral glucose ingestion may amount to <20% in patients with type 2 diabetes (5,7). The reasons underlying the loss of incretin activity in type 2 diabetes are still incompletely understood. The present article reviews the available evidence regarding disturbances in the enteroinsular axis in patients with type 2 diabetes and provides possible explanations for their etiologies, focusing on the personal experience of the authors. ### Secretion of incretin hormones in patients with type 2 diabetes. Because the incretin effect has been related to the secretion and insulinotropic action of GIP and GLP-1 (8,9), it was obvious to compare these parameters between patients with type 2 diabetes and healthy control subjects: Regarding the secretion of GIP, elevated, normal, and reduced plasma levels have been described in patients with type 2 diabetes (10–15). However, taking together all the evidence available, the secretion of GIP appears to be relatively unchanged in type 2 diabetic patients. For GLP-1 release, the case is even more complex. Several studies have reported significant reductions in GLP-1 levels after mixed meal ingestion in patients with type 2 diabetes (10,16,17). In addition, one study has found minor impairments in GLP-1 levels in individuals with impaired glucose …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The current consensus in the literature is that GLP-1 and GIP circulation levels are comparable between T2D patients and nondiabetic controls in response to nutrient challenges.158”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“By these means, the hyperglycemia in patients with type 2 diabetes can readily be normalized by the intravenous administration of GLP-1 (26), even at relatively low doses (27).”
BackgroundSelf-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Research works printed but not linked: 5
- Meier, 2005, Insulin secretion, 961
- Ebert, 1980, Hypo- and hypersecretion of GIP in maturity-onset diabetics (Abstract), Diabetologia, 19, 271
- Nauck, 2004, Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes, Diabetes, 53, S190, 10.2337/diabetes.53.suppl_3.S190 · DOI · Paper page
- Knop, 2007, Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?, Diabetes, 56, 1951, 10.2337/db07-0100 · DOI · Paper page
- Pfeifer, 1981, Insulin secretion in diabetes mellitus, Am J Med, 70, 579, 10.1016/0002-9343(81)90579-9 · DOI · Paper page
Cited by
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Self-citationType 2 diabetes across generations: from pathophysiology to prevention and management
Nolan, C. J., Damm, P., & Prentki, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60614-4 · Cited by 923
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Self-citationReed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Metadata
- Authors
- Meier, J. J., & Nauck, M. A.
- Affiliations
- St. Josef-Hospital (DE)
- Diabeteszentrum Bad Lauterberg (DE)
- Corresponding author
- Meier, Juris J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-05-01
- Volume
- 59
- Issue
- 5
- Pages
- 1117-1125
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2857890
- OpenAlex
- W2097621088
- Cited by
- 215
- References
- 72
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 14 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 5 · 2019: 15 · 2018: 8 · 2017: 16 · 2016: 16 · 2015: 17 · 2014: 16 · 2013: 27 · 2012: 19
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, enteroinsular axis, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretin secretion, postprandial insulin secretion, beta-cell mass, insulin resistance
- MeSH terms
- Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Models, Biological, Insulin-Secreting Cells, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function? https://app.cochat.ai/papers/10.2337/db09-1899
- The paper
- Meier, J. J., & Nauck, M. A. (2010). Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function? Diabetes. https://doi.org/10.2337/db09-1899
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.